BCOP Self-Study Online Module Release II
The Self-Study Online Modules will cover all BCOP domains and multiple hematology/oncology patient populations, you will learn from:
- Leading experts from a variety of specialties and settings
- Therapeutic developments translated into case-based reviews
- Application of information to practice based scenarios
The Self-Study Online Module features current articles from primary oncology literature which are available on demand and allow you to complete at your convenience. The modules will allow the learner to apply literature they have and read in patient cases and/or case – based discussion. Credit given per module – choose one or all.
Module 5: Advances in the Diagnosis and Treatment of Acute Graft-versus-Host Disease (2.0 BCOP/ACPE)
Module 6: Anticoagulation – NOAC Agents in Oncology and Reversal Agents (2.0 BCOP/ACPE)
Module 7: New Updates in Gastric and Gastroesophageal Junction Adenocarcinoma (1.5 BCOP/ACPE)
Module 8: Melanoma - Pharmacoeconomics (1.5 BCOP/ACPE)
Each module will include access to articles, pre-assessment questions, patient cases and/or case—based discussion and the BCOP web-based post-test. Your purchase includes all four modules. You may choose to complete all 4 modules or select ones individually and still receive BCOP credit for modules which achieve passing scores.
New this year, the case studies will count towards the overall test score for the BCOP credit. Therefore, between your results in the Case Studies and the Posttest questions will determine your total score which still must meet the 75% threshold for passing to earn BCOP credit.
Release II offers up to 8 BCOP/ACPE credits
HOPA Member Price: $165
Non-Member Price: $225
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and post-test, with a passing grade of 75% achieved. BCOP test must be completed by March 29, 2019.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and posttest, with a passing grade of 75% achieved. Test must be completed by March 29, 2019.
Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict: Planners and Managers Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.
Module 5: Advances in the Diagnosis and Treatment of Acute Graft-versus-Host Disease
Katie Gatwood, PharmD BCOP
Venderbilt University Medical Center
Graft-versus host disease (GVHD) remains one of the leading cause of non-relapse morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT). New data has recently emerged regarding the use of certain biomarkers as a predictor of GVHD-related mortality. Corticosteroids have historically been the cornerstone of GVHD treatment without any standard consensus on the use of second-line therapeutic options. In 2016, ruxolitinib gained one of the first-ever FDA breakthrough therapy designations for steroid-refractory acute GVHD treatment. This self-study module will focus on the clinical data regarding the use of biomarkers for risk stratification of acute GVHD as well as Janus Associated Kinase (JAK) inhibition in steroid-refractory acute GVHD and application to select optimal therapy based on patient- and disease-specific characteristics.
Katie Gatwood, PharmD BCOP
Dr. Gatwood received both her undergraduate and pharmacy degrees from the University of Michigan in Ann Arbor, MI. She then went on to complete both her PGY1 and PGY2 Oncology residencies at University of North Carolina Health Care in Chapel Hill, NC. After completion of her post-graduate training, Katie began her career as a Pediatric Stem Cell Transplant Clinical Pharmacist at Vanderbilt University Medical Center in Nashville, TN. She practiced for 1.5 years in this role before transitioning to a Stem Cell Transplant Clinical Pharmacist position in the Adult Stem Cell Transplant program at Vanderbilt to assist in the expansion of clinical pharmacy services to the outpatient setting. Katie has been an active member of both HOPA and ASBMT for several years and currently serves on committees in both organizations. She is actively engaged in research and is passionate about improving pharmaceutical care for the stem cell transplant population as well as advocating for the role of the pharmacist in their care.
Disclosure: Jazz Pharmaceuticals – Speaker - honoraria
- Evaluate the use of biomarkers in the diagnosis and grading of graft-versus-host disease.
- Discuss the role of Janus Associated Kinase signaling and modulation in the management of acute graft-versus-host disease.
- Recommend a patient-specific treatment and monitoring plan for patients receiving ruxolitinib for steroid-refractory acute graft-versus-host disease.
Target AudienceThis activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 2.0 contact hour (.20 CEUs) under the ACPE universal activity number 0465-0000-18-071-H04-P.
Module 6: Anticoagulation – NOAC Agents in Oncology and Reversal Agents
Christine Cambareri, PharmD BCPS BCOP
Hospital of the University of Pennsylvania - Philadelphia
Focused review on updates in anticoagulation using novel oral anticoagulant therapy oncology patients in the past year and discussion around experience with novel oral anticoagulation reversal agent, idarucizumab.
Dr. Christine Cambareri
Dr. Christine Cambareri received her doctor of Pharmacy degree from Albany College of Pharmacy and Health Sciences - Vermont Campus in 2013 and completed two years of post-graduate residency training in pharmacotherapy at Christiana Care Hospital in Newark, Delaware and in Hematology/Oncology at Yale New Haven Health System. Since 2015, Dr. Cambareri has worked as an Outpatient Clinical Oncology Pharmacy Specialist at the Hospital of University of Pennsylvania’s Abramson Cancer Center.
Disclosure: No financial relationships exist with commercial interests.
- Demonstrate understanding of the recent data for use of edoxoban in cancer patients.
- Compare the data for oral anticoagulants versus warfarin in patients with cancer and atrial fibrillation to best optimize treatment interventions.
- Formulate recommendations around dosing and administration of idarucizumab.
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 2.0 contact hour (.20 CEUs) under the ACPE universal activity number 0465-0000-18-072-H04-P.
Module 7: New Updates in Gastric and Gastroesophageal Junction Adenocarcinoma
Jane E. Rogers, PharmD BCOP
MD Anderson Cancer Center
The following self-study module will review the latest discoveries in localized and advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Recent perioperative results are reviewed along with biomarker updates and available therapies in the advanced unresectable setting.
Jane E. Rogers
Jane E. Rogers is a Clinical Pharmacy Specialist at the University of Texas M.D. Anderson Cancer Center in Houston, TX. Dr. Rogers earned her Doctor of Pharmacy degree in 2008 at West Virginia University School of Pharmacy in Morgantown, WV. She went on to complete an ASHP-Accredited Pharmacy Practice Residency at West Virginia University Hospitals in Morgantown, WV, and an ASHP-Accredited Pharmacy Oncology Residency at the University of Texas M.D. Anderson Cancer Center in Houston, TX in 2009 and 2010 respectively. She is board certified in oncology pharmacy and currently works in the Gastrointestinal Medical Oncology Clinic at the University of Texas M.D. Anderson Cancer Center in Houston, TX.
Disclosures: No financial relationships exist with commercial interests.
- Compare the various treatment regimens and strategies for localized gastric or GEJ adenocarcinoma
- Employ an appropriate treatment strategy for a localized gastric or GEJ adenocarcinoma given patient and tumor characteristics
- Choose a treatment plan for advanced unresectable gastric or GEJ adenocarcinoma based on patient and tumor characteristics
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.5 contact hour (.15 CEUs) under the ACPE universal activity number 0465-0000-18-073-H04-P.
Module 8: Melanoma - Pharmacoeconomics
Ali McBride, MS PharmD BCPS BCOP FAzPA
The University of Acizona Cancer Center
The emergence of immunotherapies into various disease states, including melanoma, has provided a new opportunity for treatment in patients. Immunotherapy offers new treatment options, including the checkpoint inhibitors of cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed cell death-1 (PD-1) protein, and viral vectors. These new treatments provide unique mechanisms of action for patients with stage III or IV melanoma, improving overall outcomes. The cost of immunotherapies and evaluation of outcomes adds another determinant for patients when they are selecting therapy, especially in light of new alternative payment models for cancer care. The utilization of pharmacoeconomics in cancer care is becoming a prevalent discussion for immunotherapy cancer treatment. Oncology pharmacists must understand pharmacoeconomics when helping patients and providers select the most appropriate and cost-effective therapy.
Ali McBride is the Clinical Coordinator of Hematology/Oncology at The University of Arizona Cancer Center. He currently serves as Secretary of the Association of Community Cancer Centers (ACCC) and he has been actively involved with the American Society of Health-System Pharmacy (ASHP) and the Hematology Oncology Pharmacy Association(HOPA).
Dr. McBride has been working on oncology drug shortages and has testified on behalf of HOPA at FDA Drug Shortage Workshop, presented on behalf of ACCC at the Washington DC Congressional Session and was an invited member of the ASHP Drug Shortage Stakeholders Meeting. Dr. McBride is also actively involved with Biosimilar regulation and the pharmacoecomic impact of biosimilars into the US Marketplace. He currently serves as a working group member for HOPA on its biosimilar committee. In addition, he currently serves on the National Quality Forum Cancer Standing Committee and as an ACCC ICLIO Scholar. He has published numerous articles focusing on drug shortages, immunotherapy outcomes and side effects, oral adherence, stem cell transplant and pharmacoeconomics.
Disclosures: Merck – Speaker – Honoria
- Summarize the incidence of metastatic melanoma in the cancer population and evaluate current treatment options and outcomes.
- Evaluate different types of pharmacoeconomic analysis that could be used to address cost and value options for patients in this setting.
- Choose a pharmacoeconomic model to address a total cost of care model with Immunotherapy for treatment at your facility.
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.5 contact hour (.15 CEUs) under the ACPE universal activity number 0465-0000-18-074-H04-P.